Abstract: Human immune deficiency virus (HIV) and human hepatitis C virus (HCV) infection are frequent in patients who have been exposed to blood or blood-derived products. It has been suggested that HIV infection increases HCV replication altering the course of HCV-related disease. However, it is not known if HIV directly enhances HCV replication or if its effect is the consequence of HIV infection of other cell types that control HCV replication (lymphocytes, macrophages). While the main cell targets for HIV infection are mononuclear leukocytes bearing CD4 and the chemokine receptors CCR5 and CXCR4, HCV was originally thought to be strictly hepatotropic, but it is now known that HCV can also replicate in peripheral blood mononuclear cells (PBMC). Therefore, in co-infected individuals, these two different viruses could share cell targets and interact either directly or indirectly. Some membrane receptors can be used by both HCV and HIV for entry into target cells, but the intracellular mechanisms shared by these viruses are not known. Lack of experimental systems providing suitable methods for the study of HCV replication in the presence or absence of HIV coinfection has hampered advances in this research area, but recent investigations are currently going on in order to answer these questions. This is an important issue, as knowledge of HIV/HCV interactions is required for the design of effective antiviral therapies.
INTRODUCTION
Human immune deficiency virus (HIV) and human hepatitis C virus (HCV) infection are frequent in patients who have been exposed to blood or blood-derived products. While the main cell targets for HIV infection are mononuclear leukocytes bearing CD4 and the chemokine receptors CCR5 and CXCR4, HCV was originally thought to be strictly hepatotropic. There is mounting evidence that HCV can also replicate in peripheral blood mononuclear cells (PBMC). Therefore, in co-infected individuals, these two different viruses could share cell targets and interact either directly or indirectly. It has been suggested that HIV infection could enhance HCV replication in co-infected patients [31, 144] . In HCV/HIV co-infected individuals (HCV/HIV), progression to hepatic fibrosis and liver cirrhosis have been observed [25, 47] . Likewise, progression to cirrhosis and terminal hepatic disease are increased during HCV/HIV coinfection [139] . The effectiveness of anti-HCV treatment is reduced in HCV/HIV [73] , and plasmatic or hepatic viral load are higher in these patients than in those that had been infected with HCV alone [31, 144] . There is also evidence that acute HCV infection can raise HIV viremia in persons with otherwise well-controlled illness, and co-infection with HCV may accelerate progression from HIV infection to AIDS [47, 123] . The precise mechanisms that permit HCV and HIV to interact have not been well characterized, as a convenient experimental system for their study is not available.
In this review, we shall address the subject of in vitro HCV/HIV interaction, the steps of the immune process at *Address correspondence to this author at the Laboratory of Immunology, Academia Nacional de Medicina, Pacheco de Melo 3081 (1425), Buenos Aires, Argentina; E-mail: ruibalbea@hematologia.anm.edu.ar § The contribution of CP and LB to this review was equal.
which these viruses are most likely to interact by sharing either membrane receptors, intracellular pathways or regulatory mechanisms, as well as the experimental systems that can be useful for future studies of their interplay. We will first focus on the role of dendritic cells (DC) in the initial steps of HCV and HIV infection, because there is mounting evidence that these cells have a key role in the assembly of an effective immune response against most pathogens. Moreover, DCs are known to possess receptors that can be used by HCV and HIV for the entry into the immune circuits and for infection. We will then examine the role of cytotoxic effectors in the control of HIV and HCV expansion. Finally, we will concentrate on the development of in vitro methods that may be useful to study HIV/HCV interaction at the cellular level.
Initial Steps of HIV and HCV Infection: DC as First Line Receptors of Viral Infection and as Key Players of the Immune Response to HIV and HCV
DC are nature's sentinels for initiating immune responses to invading pathogens and altered host cells. However, viral pathogens can use DC as vehicles for subverting the immune response and establishing infection in the host. Apparently, DC play an important role in HIV infection by sequestering the virus from its entry portal at mucosal sites and transferring it to lymphoid organs. HCV can also bind to C-lectin receptors (CLR) present in DC and these receptors are thought to open the way for DC infection and subsequent HCV replication in these cells [40, 81] .
DC are the main antigen-presenting cells (APC) regulating the T cell response [8] . In the absence of external stimuli, DC remain in a resting state in which they have only a limited ability to prime naïve cells. However, in response to infection, DC undergo many phenotypic and functional changes which coordinately result in an improved ability to interact with T cells and promote T cell clonal expansion and differentiation. Immature DC, including Langerhans cells, splenic marginal zone DC and interstitial DC within lymphoid tissues, continuously sample self-antigen to maintain T-cell tolerance. Foreign antigens can also be grabbed by immature DC. If these cells are directly triggered by pathogens through their pattern-recognition receptors (like toll like receptors, TLR) [28] , or indirectly induced though exposure to endogenous danger signals, such as material released from damaged cells or inflammatory mediators, they mature to immunogenic mature DC. Different TLR are used to recognize different classes of signals (derived from viruses, bacteria, damaged cells, etc); this is central to their role as sentinels of innate immunity and as translators of innate immunity into adaptive immunity [113] . It has been recently shown [50, 107, 137] that there is heterogeneity in the effector function of mature DC (licensed and unlicensed DC) according to the nature of the maturation stimulus. In some cases, interaction of pathogens with TLR does not lead to the generation of classic functional mature DC. It has been proposed that interaction of immature DC with HIV may lead to a semimature state whereby immature DC migrate to the lymph nodes but do not reach full maturation into mature DC. In this situation, semimature DC induce a state of tolerance rather than immunity to antigens [70] . DC constitute about 1% of peripheral blood mononuclear cells and can be divided into 2 major subpopulations that are phenotypically and functionally distinct: myeloid-derived dendritic cells (MDC) and plasmacytoid DCs (PDC) ( Table 1) . MDC are the most crucial APC involved in innate and adaptive host response to viral infections. Considerable work has been done using MDC obtained by in vitro stimulation of peripheral blood monocytes with growth stimulating factors. In vitro, under IL4 and granulocyte-macrophage colonystimulating factor (GM-CSF) growth conditions, CD14+ monocytes change to highly potent CD14-APC, termed monocyte-derived dendritic cells; CD34+ cells can also serve as in vitro precursors for MDC-like cells. The second subpopulation of migrating blood DC, termed PDC are distinguished from MDC because they do not express CD11c, they express high levels of CD123 (IL3 receptor) and produce high amounts of the antiviral protein IFN-, in response to HIV and other virus infections [18, 29, 100] . Thus, PDC are important in innate immunity to viral infections. Unlike MDC, which migrate to tissues and intercept invading pathogens before their migration to the lymph nodes, PDC migrate directly from blood to the secondary lymphoid tissue. Differentiation of blood monocytes in the presence of IFN-and GM-CSF leads to DC expressing TLR-7 that exhibit many of the functional characteristics of PDC [93] , indicating that DC precursors can expand and differentiate into cells of diverse phenotype and function influenced by the composition of the surrounding milieu and the nature of the differentiating stimulus.
HIV Binding and Infection of DCs
Migrating DC are probably responsible for transport of HIV to T cell regions of draining iliac or colonic lymph nodes. Infection of an activated CD4 lymphocyte is more efficient when the virus is transferred during a DC-T cell response (Fig. 1) . During the early phase of HIV replication in vivo, this DC-T lymphocyte synergy could play a major role in initial viral replication [156] .
Although with lower frequency than macrophages and activated CD4+ T lymphocytes, both DC types (MDC and PDC) could be infected by HIV-1 in vitro and in vivo [86] . However, virus replication was more efficient in PDC. Isolation of highly purified MDC and PDC obtained from HIV-1 infected patients, demonstrated that both subpopulations were infected with HIV and that some MDC contained integrated provirus [86] . Also, both populations were severely impaired in their ability to stimulate T-lymphocyte proliferation. Loss of circulating MDC and PDC is likely to be an important factor in the decline of acquired and innate response in HIV-1 infection.
In addition, thymic DC subsets can be infected by HIV, sustaining high levels of HIV replication. HIV-infection of thymic DC had cytopathogenic effects leading to DC death in accordance to the level of viral replication. Thus, in addition to cooperate in the expansion of HIV infection in the thymus, DC infection by HIV could affect thymopoiesis in infected individuals [126] .
The C-type lectin DC-SIGN (CD209), present in immature DC, was initially suggested to play a key role in HIV dissemination by DC in vivo [41, 147] . However on certain DC subsets identified in vivo, other C-type lectin receptors (CLR) such as langerin, on Langerhans cells (LCs), as well as mannose receptors (MR), on dermal DC, must be more relevant [147] . Therefore, DC-SIGN although important, may represent only one of several CLR present on DC that are able to interact with HIV in vivo [115, 148] . It has been postulated that DCs are just cellular viral "Trojan horses", which transfer virus to permissive cell types via DC-SIGN binding without being infected themselves. Several authors [71, 89, 97] have shown that DC-SIGN binding results in HIV internalization in DC-SIGN-transfected cells. However, recently it was suggested that DC-SIGN-mediated internalization was dispensable for enhancement of HIV-1 transfer from DC to T cells. Apparently, DC-SIGN would facilitate DC infection, with subsequent transfer of newly synthesized, DC-derived viral particles to T cells [19] . Direct transfer of HIV from the endosomal pathway of DC to CD4 lymphocytes is unlikely to be selective for CXCR4 or CCR5 HIV co-receptors, whereas "de novo" infection of DC is likely to select for CCR5 tropic virus.
endothelium, but not on DC. This DC-SIGN related molecule (DC-SIGNR) has also the capacity of binding HIV gp120 and is co-expressed with DC-SIGN at low levels on lymph node sinus endothelium. Therefore, it could also contribute to HIV transfer at this site [12, 105, 106] .
Loss of PDC as a Result of HIV Infection
Loss of DC alone would lead to a decline in Tlymphocyte responses through impaired antigen presentation. In addition, specific loss of DC involved in the release of mediators (inflammatory cytokines, interferon) that are important for the balance of the immune response would further affect the ability of the HIV infected host to control opportunistic infections and maintain an intact immune defense system [32] . It has been proposed that MDC and PDC play opposing roles in HIV infection of T cells. While MDC appear to facilitate HIV infection through capture of the virus and transmission to T cells, PDC would inhibit HIV replication in T cells through the secretion of IFN-and other small molecules [48] .
The absolute number of circulating PDC (> 2 cells/μl) can be used to monitor the immune system in HIV-infected patients. The number of PDC (INF-producing cells) in the blood is markedly reduced in AIDS patients but increased in asymptomatic HIV+ long term survivors [100] . The PDC number may decline to low levels and then remain relatively constant even when the CD4 levels continue to drop [136] . The concept that both PDC and CD4+ T lymphocytes can be independently impaired after HIV infection was corroborated by the study that compared the production of INF-(which is mainly PDC dependent) versus CD4 levels in a large cohort of HIV-infected patients [132] . These deficiencies were found not only in terms of absolute numbers of DC/μl of blood but also in terms of their relative number, indicating that there was a selective loss of these subpopulations that cannot be attributed to generalized leucopenia. A possible explanation for the loss of PDC in HIV-infected patients is that they could have left the peripheral blood to enter into the secondary lymphoid organs or tissues. However, the plasma viral load of HIV was found to significantly correlate with the levels of functional IFN--producing cells (as measured by ELISPOT), rather than with the absolute numbers of PDC. Susceptibility to opportunistic infection and disease progression did not occur unless both the IFN-production and the CD4+ T cell level were critically compromised [132] . Table 2 summarizes the consequences of HIV infection on DC balance and function. 
HCV Binding and Infection of DC
A remarkable feature of HCV infection and the ensuing HCV-associated disease is the ability of this virus to persist in the majority of infected individuals [30] . Anti-HCV therapy (recombinant IFN-in conjunction with the nucleoside analog ribavirin) is not fully adequate and only temporarily effective in most cases [43, 52] . HCV is a small, enveloped, plus-strand RNA virus belonging to de Flaviviridae family. Its genome is a single strand RNA 9600 nucleotides in length, encoding a single polyprotein that is processed into structural proteins located at the N-terminus (core, E1, E2 and p7) and 6 non structural proteins [11, 46, 51] . The identity of the receptor for HCV remains elusive. The low density lipoprotein (LDL) receptor (LDLR) has been shown to mediate internalization of HCV particles associated to LDL [35] . The tetraspanin CD81 has been identified as a high affinity binding receptor for recombinant E2 from HCV genotype 1a [157] . However, since LDLR and CD81 are expressed in most cell types, the hepatic tropism of this virus cannot be ascribed to the presence of these membrane molecules [163] . Viral infection is characterized by a high rate of chronicity that in 20% of the cases leads to liver cirrhosis, with the eventual development of hepatocellular carcinoma [128] . This virus is highly variable and exists in infected persons as a quasispecies that consists of a pool of related but genetically distinct variants [133] . Replication of the HCV genome has been demonstrated in primary hepatocytes and hepatocyte cell lines [53] as well as in hematopoietic cells [9, 10, 111] . Since the genomic sequence of HCV was determined, progress has been made towards understanding the function of the HCV encoded proteins, although lack of an efficient in vitro replication system or a small animal model for experimental infection has hampered unraveling the complex nature of HCV/host interaction. The report of HCV-RNA in PBMC suggests that separate HCV reservoirs may coexist and that HCV may use different receptors to infect different cells [75] . Recently, the role of CLR as receptors of HCV has been raised [81] . Thus DC-SIGN and a related CLR molecule present in the endothelium lining hepatic sinusoids and not in DC (L-SIGN) were shown to bind HCV envelope glycoprotein E2 through high mannose glycans. It is tempting to speculate that subsequent to binding to endothelial L-SIGN [40] , HCV could be transmitted to the surrounding hepatocytes in a "trans" interaction as proposed for HIV bound to DC-SIGN (Fig. 2) . In addition, efficient binding of soluble E2 to DC-SIGN and DC-SIGNR has also been demonstrated in cell lines and human primary endothelial cells [106] . Both mature and immature-MDC could bind soluble E2, but while DC-SIGN was required for E2 capture by immature MDC, binding of E2 to mature MDC was partly independent of DC-SIGN expression, suggesting that other surface molecules may mediate HCV glycoprotein interactions in these cells [106] .
There is evidence that, in addition to binding to DC receptors, HCV can replicate in DC obtained from patients chronically infected with HCV [6, 44, 103] suggesting that MDC may constitute a reservoir in which HCV replication takes place during natural HCV infection. Furthermore, as demonstrated for HIV infection, both MDC and PDC were depleted and their function was impaired in HCV infected patients with chronic hepatitis [61] , which may explain their poor antiviral adaptive immune response. There is controversy on the function of both PDC and MDC in HCVinfected patients. While in some studies it was reported as normal [3, 104] in other studies impaired IFN-secretion was observed in HCV patients receiving therapy (recombinant IFN-and ribavirin) and this finding was related to the number of PDC identified in the blood, suggesting that PDC depletion and decreased IFN-secretion were the consequence of treatment and not the result of viral infection per se [44] . In other studies, functional defects of DC (impaired allostimulatory function, increased IL-10 production, reduced expression of TLR2) were observed in individuals with chronic HCV infection [6, [59] [60] [61] [62] . In any case, functional defects of peripheral blood DC (mainly those of the PDC subset) could dramatically impair innate and adaptive anti-HCV immune response leading to viral persistence [42] .
Cell-Mediated Immune Response to HIV and HCV
Impaired immune response to HIV and the generalized immunodeficiency that characterizes HIV disease can be explained at least in part, because the main HIV targets are CD4 T lymphocytes and other CD4 bearing hemopoietic cells that are necessary for a correct balance of the immune system. In addition to HIV-induced cell death, infection may alter the function of CD4+ cells [131] .
On the contrary, the mechanisms whereby HCV establishes a persistent infection remain elusive [21] . Subversion of host immune responses by HCV through different evasion pathways could underlie the high rate of occurrence of chronic infection [38] . The strategies of evasion of the immune response followed by HCV are designed to bypass or ignore both the innate and the adaptive immune response [155] . In this regard, both its high rate of mutation and its ability to resist the defense machinery put forward by the adaptive immune response, help to establish chronic infection [138] . In order to prevent the occurrence of persistent HCV infection and its associated liver diseases, it will be important to establish if failure to produce an efficient immune response to HCV stems from the impact of antigen overload during immunological priming [28] , to defects of antigen presentation [158] , to hyperinduction of regulatory T cells [124] , or to other unknown reasons [155] .
CD8+ T Cells and HIV Infection
The importance of CD8+ T lymphocytes in containing HIV replication was appreciated soon after the onset of the AIDS epidemic. CD8+ T lymphocytes were shown to inhibit HIV replication in vitro in autologous lymphocytes [153] . The importance of CD8+ T lymphocytes was then demonstrated in vivo showing the expansion of CD8+ cytotoxic T lymphocytes (CTL) with oligoclonal V repertoires in acutely infected patients at a time when neutralizingantibody was absent and viremia started to decline [69] . Virus specific CTL responses have also been implicated in chronic HIV infection, in particular in patients with slow declines of CD4+ T lymphocytes, low HIV viral load in plasma and stable clinical condition [96] and in seronegative Gambian prostitutes who remained uninfected by HIV in spite of frequent exposure [118] . A significant inverse correlation was reported between the frequency of peripheral blood HIV specific CTL and plasma viral load, supporting the importance of the role of CTL in controlling HIV replication [98] . Concerning CD4+ T lymphocytes, it is possible that CD4+ virus specific T cells provide the immunological help necessary for expanding and maintaining HIV-specific CD8+ CTL [2] . In many studies, the ability of CD8+ T cells to respond to HIV antigens presented in the correct HLA context is measured in terms of their ability to synthesize IFN . However, IFN synthesis is not equivalent to the capacity of these cells to kill HIV-infected cells, and the num- ber of virus specific CD8+ T cells generally surpasses the number of infected cells replicating the virus [78] . Long term non progressor and progressor HIV-infected individuals had similar numbers of CD8+ HIV-specific T cells capable of synthesizing IFN . However, in addition to their frequency, it is important to consider breadth of epitope recognition and functional quality of HIV-specific CD8+ effector cells. In this regard it has been reported that HIV non progressors maintain highly functional HIV-specific CD8+ T cells [15] . Impaired CD8+ T cell maturation could be the cause of the CD8+ T cell defect in HIV-infected patients. Multiple factors may be involved in the development of incomplete or inefficient maturation, among them defective DC presentation, antigen initial concentration and persistence, chronic activation, the cytokine milieu, activation by CD70 expressed on B lymphocytes, cytokine receptor deficiencies, etc [5, 87, 91, 99] . As a result of these multiple factors, defense mechanisms would fail allowing HIV persistence as has been proposed in other animal models [162] .
CD8+ T Cells and HCV Infection
The development of methods useful to identify virus specific effector CD8+ T cells [72] has helped to establish the role of these cells in resolution of HCV-associated disease. Using one of the methods, the ELISPOT assay that involves the detection of cells secreting IFN , the number of HCV-specific CD8+ T cells during the first 6 months after onset of disease appeared to be associated to eradication of HCV infection [49] . However, chronic HCV infection can be established in the presence of persisting virus-specific CD8+ responses [36] . While circulating memory CD8+ T lymphocytes display the early/intermediate effector phenotype in chronic HCV+ patients [4] , they may possibly be hampered in generating efficient effector cells in vivo [36] . Interestingly, it has been shown that while HCV-specific CD8+ T cells have a T central memory (T CM )-like profile displaying surface receptors characteristic of the early/intermediate phenotype (CD27, CD28 and CCR7) [4] , they do not express the homing molecule CD62L as most T CM [82] (Table 3) . This affects not only the quality of HCV-specific CD8+ T cell responses, but also the quality of CD8+ effector T cells against other virus, such as cytomegalovirus (CMV), suggesting that HCV-infection may induce a generalized defect in the maturation of effector CD8+ T cells [82] . The frequency of CD8+ T cells recognizing HCV antigens was higher in chronic HCV than in patients who recovered from infection, but these cells were functionally impaired, as they did not proliferate or produce IFN and they failed to kill HCV-infected targets [154] . While the information on CD8+ T cell responses points to their protective role in HCV infection, CD4+ T cell responses are also important. Thus, the CD4+ T cell response against HCV persisted in acutely infected patients who cleared HCV infection, while it disappeared in those who recurred after initial control of HCV infection [42] . Preserved CD4 response to HCV would be necessary to maintain CD8+ T effector cell function during the chronic phase, as shown for other viral infections [162] . Some of the defects of DC function described before [59, 61] or their inability to secrete IL-15 [57] could be related to failure to develop an efficient CD8+ T cell response during the chronic phase. [98] .
• Defects in CD8 maturation in HIV progressor patients [4, 91] .
B.-Failure of CD8 T cells in HCV control
• Altered CD62L expression in CD8+ cells from HCV patient [82] .
• Lack of HCV-induced proliferation and IFN release or cytolysis of HCV+ targets in HCV patients [154] .
• Lack of CD8+ T cell help to induce CD8+ T effector cells in HCV patients [42] .
HIV/HCV Co-Infection and the Immune Response to Each Virus
Since HIV and HCV share common routes of infection, patients co-infected with both viruses are frequently found and there is evidence that the course of virus-associated disease is different (at least for HCV) in co-infected patients than in singly infected patients. There is evidence that HIV influences the course of HCV infection in several ways (Table 4).
Table 4. HIV/HCV Co-Infection and Immune Response to HCV
• Decreased time to progress to HCV-related liver disease in HIV/HCV co-infected than in HCV patients [76] .
• Accelerated progression to cirrhosis or liver carcinoma in HIV/HCV co-infected than in HCV patients [14, 39, 83] .
•
Higher death rate in HIV/HCV co-infected than in HCV patients [26, 77] .
First, HCV-associated disease progresses more rapidly in HIV/HCV co-infected individuals. In general HCV-related liver disease takes about 30 years in a mono-infected individual [76] but is significantly shorter in HIV/HCV infected patients [14, 83] . The cumulative number of deaths due to failure of the liver after the first exposure to HCV was four times greater in HIV/HCV individuals than in singly infected HCV patients [26] . These results were confirmed in recent studies showing that the death rate associated to hepatic disease was 7 times higher in HIV/HCV than in HCV patients, and these figures were even higher in AIDS patients [77] . The lapse required for the development of hepatocellular carcinoma was shorter in HIV/HCV patients [39] . Likewise, 25% of the patients in the HIV/HCV group developed cirrhosis after 15 years of HCV infection, while only 6.5% of singly infected HCV+ patients do it in the same period [125] . While the grade of hepatitis was associated to HIV stage and the consequent functional defect in the immune system, cirrhosis was initiated during the initial stages of HIV infection, when the function of the immune was relatively preserved [27] . There are several proposals to explain why HIV infection accelerates the course of HCV-associated disease.
In general it is attributed to the generalized state of immunosuppression caused by HIV-infection [108, 116] , but enhanced fibrogenesis [130] or increased liver infiltration by CD3+CD56+ cells (a subset of natural killer cells) [120] could also favor liver damage.
Second, HIV infection results in increased HCV viral loads [31, 88, 143] . Loss of immune control of HCV infection in HIV+ individuals, may underlie the observed increments of the HCV viral load [13, 24, 31, 88, 135, 145] . On the other hand, other authors failed to observe this inverse association between failure of the immune system and increased plasma HCV RNA [23, 114, 129, 143, 160] . How HIV infection results in increased HCV replication is not clear. Beld et al. [13] observed that independently of the immune suppression induced by HIV (reflected by decreased numbers of CD4 lymphocytes) HIV infection had an influence in the levels of HCV RNA in plasma. A role for the HIV regulator gene tat has been proposed [151] since a putative tat-binding motive in the NS4 HCV protein could be a target for the regulatory action of HIV tat [33] .
Third, the response to anti HCV treatment is lower in HCV/HIV patients than in HCV singly infected individuals. In mono-infected patients, responses to pegilated interferon and ribavirin can reach 50-80% [37, 84] , while in those that are HIV co-infected, treatment is effective only in 20-35% [73, 102] . Co-infected individuals would require higher doses of anti HCV treatment to achieve similar results to HCV singly infected individuals [94, 134] . In agreement with this, the chance of reaching spontaneous clearance of HCV infection are reduced from 10-15% in the HCV group to 2.5% in the HIV/HCV group [1, 24, 142, 150] . Clearance has been associated to a strong and sustained CD4 response that is necessary to induce an effective CD8 response against HCV. In addition to the effects of HIV infection per se on HCV-disease evolution, one must consider the impact of highly active antiretroviral therapy (HAART). It has been shown that initiation of HAART can have an effect on HCV viral load. HCV viral load was shown to increase [109, 112, 122] in some cases with temporary increase in the hepatic transaminases [22, 117, 122, 149] . However, HAART treatment has a beneficial long term effect on HCV-associated liver disease [85, 110, 146] . The effects of HAART can be indirect, through their influence on the immune balance or on the recovery of cells that can be targets for HCV infection [34, 90, 101] .
Data regarding the effects of HCV infection on HIV disease progression are not clear. Initial reports suggested that HCV infection accelerated progression to AIDS [47, 123] , but these results were not confirmed by further studies [140] . In spite of this, there is evidence that HCV infection can generally affect the function of cells that are central for the assembly of an efficient immune response against HIV and other viruses [45, 82] . Therefore, both viruses could mutually affect the mechanisms that control their persistence and expansion.
Experimental Systems for the Study of HCV/HIV Interaction
In vitro systems for the study of HIV replication, cell cycle and molecular biology are widely used [68] . Unfortunately, the absence of an efficient culture model that could reproduce virus life cycle has severely limited the analysis of many aspects of HCV infection. Primary hepatocyte cultures and hepatocyte cell lines have been used to study HCV infection in vitro [56, 63, 121] . However, reproducibility of the results and HCV replication levels were low. On the other hand, HCV infection of different target cells using HCV+ serum did not provide satisfactory results due to the variability of serum-derived virus infectivity [11] . In 1999, a culture system that is suitable for the study of various aspects of HCV RNA replication and persistence became available and its advantages have been reported [80] . The "replicon system", an experimental model that allows efficient propagation of HCV replicons in Huh-7 (a human hepatoma cell line) has been useful for the study of HCV. Replicons are subgenomic or genomic units of HCV obtained on the basis of consensus genomes cloned from the liver of HCV infected patients [64, 80] . The recent establishment of a robust cell culture model that produces infectious HCV particles provides a powerful tool for the analysis of host-virus interactions and the screening of antiviral compounds [21, 79, 164] . Based on this model, different systems of HCV replication are currently being applied to elucidate many aspects of the virus-host interactions including viral entry, assembly and release that were previously unapproachable [17, 55, 58, 92, 159] .
Regarding animal models, infection of chimpanzees provides means to study HCV infection, albeit at a high cost and with the limitations of the experimental use of species that may be approaching extinction [11] . An alternative is the use of transgenic mice expressing HCV proteins [65, 67] , or experimental infection obtained by transplant HCV infected liver fragments into lethally irradiated mice reconstituted with bone marrow from immunodeficient mice (SCID mice) [54] . While these models have provided adequate means for the study of direct antiviral effects or gene therapy, they can not be used for the analysis of the immune response to HCV.
In order to solve the issue of HCV/HIV interaction it is necessary to obtain experimental models where the influence of one virus on the other can be studied at the cellular level in a system that allows the analysis of a few variables at a time.
Using in vitro infection systems, Laskus and collaborators have demonstrated that HIV could facilitate replication of HCV in native human macrophages either by rendering cells more susceptible to HCV infection or by increasing HCV replication. Although the mechanisms by which HIV facilitates HCV infection are still unclear, a positive correlation between HIV viral load and levels of HCV replication in macrophage cultures has been observed in the early stage of infection [74] .
Some reports based on the addition of viral proteins to hepatocyte lines or primary hepatocyte cultures revealed that the two viruses had synergistic effects on the regulation genes of the infected cells. In vitro models demonstrated viral interactions showing that HCV and HIV structural proteins might injure uninfected hepatocytes by an "innocent bystander" mechanism. The authors could demonstrate that signaling pathways could be involved in hepatic injury in coinfected patient cells [7, 95] .
Other studies reporting possible interactions between both viruses were based, in general, on speculations on indirect clinical or immunological/virological parameter observations in coinfected individuals [13, 24, 116, 142] . Due to the lack of a culture system that could support efficient HIV and HCV replication, a direct influence of HIV genes on HCV replication is more difficult to prove.
Some of the aspects of HIV/HCV interplay could be analyzed taking advantage of the possibility of performing long term culture of PBMCs from HIV and HCV/HIV patients in the absence of exogenously added stimuli [9, 119] . HIV coinfection influenced the frequency of HCV productive cultures derived from PBMCs and an enhancing effect of HIV on HCV persistence and replication in vitro was demonstrated. In the HIV group the probability of obtaining HCV replication in PBMC cultures was related to the CD4+ cell count and to the presence of HIV viremia. Low CD4 T cell counts affecting the magnitude and breadth of CD8 immunological control against HCV [66] may be the cause of the higher frequency of HCV+ cultures observed in the non responder group of patients. On the other hand, the presence of HIV viremia could be facilitating PBMC infection by HCV in vivo [74] , resulting in an increased possibility of generating a positive HCV culture (more cells infected by HCV, more probability to escape from immunological control and give an HCV+ culture) [10] .
In order to elucidate events of HIV direct or indirect impact we performed HIV infection assays on PBMC cultures of HCV monoinfected patients. Production of HCV after HIV infection in culture was increased 1 or 2 logs compared to uninfected controls (Fig. 3) . On the contrary, HIV infection didn't modify those cultures that were HCV nonproducers. Nevertheless, lack of sensitivity of the assay could account for the absence of HCV RNA. These preliminary results suggest a direct HIV/HCV interaction, since HCV detection occurred after the peak of HIV maximum replication (Fig. 3) . Although B cell activation, with the consequent HCV viral load increase, may be other cause of the observed changes after HIV infection in PBMC cultures, unspecific stimulus didn't account for the HCV viral burden increase. Taken together these results suggest that non stimulated PBMC culture provides a suitable system to obtain HCV replication in leukocytes in vitro. Under these conditions the influence of HIV on HCV infection could be addressed more directly.
Several questions need to be answered:
1)
Does HIV directly enhance HCV replication or is this effect the consequence of HIV infection of other cell types that control HCV replication?
2) Do HIV and HCV infect the same cells in vitro?
3)
What is the effect of HCV infection on HIV replication?
4)
Are the experimental assays selective for a given HCV genotype, and if so, how does this correlate with the in vivo genotype balance? While a lot of work needs to be performed, it will be encouraging to develop relatively simple systems to focus on some of these questions in order to try to understand the interplay of these viruses that frequently co-infect the same patients.
CONCLUSIONS
It is clear that HIV infection alters the pattern of progression of HCV disease, leading to increased mortality and morbidity in co-infected patients. Shared receptors for viral entrance (as DC-SIGN) and/or intracellular pathways, altered immune defense caused by HIV-induced immunosuppression as well as interference in presentation, antigen processing or effector cell function may be part of HIV/HCV interaction leading to increased HCV replication and persistence. However, it will be necessary to develop experimental systems that allow simultaneous cellular infection with the two viruses in order determine if such an effect is a direct one. In this regard, the use of non stimulated PBMC culture could provide help to study the interaction of HCV with HIV, at least in this target cell system.
